(HealthDay News) — For patients with type 2 diabetes, the risk for acute myocardial infarction (MI) is not significantly different for long-acting insulin analogs vs. other basal insulin therapies, according to a study published in Diabetes, Obesity and Metabolism.
Bianca Kollhorst, from the Leibniz Institute for Prevention Research and Epidemiology in Bremen, Germany, and colleagues examined the risk of acute MI in patients with type 2 diabetes in a retrospective cohort study. The risk for acute MI was compared for patients treated with long-acting insulin analogs vs. other basal insulin therapy.
The researchers identified 21,501 new insulin users. Patients treated with premixed insulin were older than those treated with analog or human neutral protamine Hagedorn (NPH) insulin (mean age, 70.7 vs. 64.1 and 61.6 years, respectively); they also had a higher number of comorbidities.
There was no significant difference in the risk for acute MI for those receiving NPH or analog insulin (HR=0.94; 95%, 0.74-1.19), but the risk was higher for premixed vs. analog insulin (HR=1.27; 95% CI, 1.02-1.58).
There was no increased risk for premixed insulin in propensity score-matched analysis.
“In contrast to a former database study, no difference was observed for the risk of AMI between long-acting analog and NPH insulin in this study,” the researchers wrote. “Neither long-acting analog insulin nor premix insulin appears to be associated with acute MI in patients with type 2 diabetes.”
Two authors are employed by Sanofi-Aventis, which funded the study.